Literature DB >> 17483983

Double-contrast magnetic resonance imaging of hepatocellular carcinoma after transarterial chemoembolization.

Nicolae Bolog1, Thomas Pfammatter, Beat Müllhaupt, Gustav Andreisek, Dominik Weishaupt.   

Abstract

BACKGROUND: The purpose of this study was to assess the accuracy of double-contrast magnetic resonance (MR) imaging for the treatment response evaluation of hepatocellular carcinoma (HCC) in cirrhotic liver after transarterial chemoembolization (TACE).
METHODS: Twenty-two patients with 30 HCC nodules treated by TACE underwent double-contrast MR imaging 1 month after treatment. MR images were obtained before and after the sequential administration of superparamagnetic iron oxide (SPIO) and gadopentetate dimeglumine contrast agent within the same imaging session. Two observers retrospectively assessed all treated nodules for evidence of residual viable tumor after TACE. The diagnostic performance of gadolinium-enhanced, SPIO-enhanced, and double-contrast enhanced images was calculated. Histopathological and angiographical findings served as standard of reference. Receiver operating characteristic curves and areas under the curves (A (z)) were calculated.
RESULTS: Double-contrast technique (A (z) = 0.95) was significantly (p = 0.036) more accurate than SPIO-enhanced technique (A (z) = 0.92) and gadolinium-enhanced technique (p = 0.005) (A (z) = 0.81) in viable tumor detection after TACE. Double-contrast technique was significantly more sensitive (92%) than SPIO-enhanced technique (80%) and gadolinium-enhanced technique (68%). Kappa values for interobserver agreement ranged from 0.67 to 0.87 and were significantly different from zero (all p < 0.001).
CONCLUSIONS: Compared to gadolinium-enhanced and SPIO-enhanced techniques, double-contrast technique significantly improves the detection of viable tumor in HCC after TACE.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17483983     DOI: 10.1007/s00261-007-9244-y

Source DB:  PubMed          Journal:  Abdom Imaging        ISSN: 0942-8925


  3 in total

1.  Synergistic enhancement of iron oxide nanoparticle and gadolinium for dual-contrast MRI.

Authors:  Fan Zhang; Xinglu Huang; Chunqi Qian; Lei Zhu; Naoki Hida; Gang Niu; Xiaoyuan Chen
Journal:  Biochem Biophys Res Commun       Date:  2012-08-07       Impact factor: 3.575

2.  mRECIST criteria and contrast-enhanced US for the assessment of the response of hepatocellular carcinoma to transarterial chemoembolization.

Authors:  Hippocrates Moschouris; Katerina Malagari; Marina G Papadaki; Ioannis Kornezos; Konstantinos Stamatiou; Antonios Anagnostopoulos; Katerina Chatzimichael; Nikolaos Kelekis
Journal:  Diagn Interv Radiol       Date:  2014 Mar-Apr       Impact factor: 2.630

3.  Nuclear imaging for functional evaluation and theragnosis in liver malignancy and transplantation.

Authors:  Jae Seon Eo; Jin Chul Paeng; Dong Soo Lee
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.